| GlaxoSmithKline Makes Aggressive Play for Emerging Markets ChinaBio Today submits: Because GlaxoSmithKline (GSK) wants to double its China and India revenues by 2015, the company will significantly reduce its prices – as much as 70% – to raise revenues. The company readily admits it is trailing its multinational rivals such as Pfizer (PFE) and Sanofi-Aventis (SNY) in developing markets.Abbas Hussain, President of Emerging Markets for Glaxo, said in an interview with Bloomberg News:Complete Story » seekingalpha.com |
Hospitals' Woes Grow With State Cuts Chiefs at some of New York City's largest hospitals say that state cuts in Medicaid and other health-care spending passed by the legislature would harm financially weak health centers and could force even stronger ones to cut workers or care. online.wsj.com |
Penwest: Change Is Coming ValueHuntr submits:Penwest Pharmaceuticals Co. (PPCO) on Tuesday announced that its Board of Directors has approved certain changes to the Company’s corporate governance practices that are designed to make the Board more responsive to shareholder input and accountable for its performance. The Company also announced that Kevin C. Tang has been selected as Chairman of the Board.Some of you may remember Kevin Tang from his almost succesful bid to liquidate Vanda Pharmaceutical (VNDA) last year as it traded below its net cash value. Mr. Tang ended up withdrawing his request for dissolution after the FDA approved its drug Fanapt, which caused shares of Vanda to skyrocket 900% in a single day. To this day, that remains one of our best investments, and we are glad Mr. Tang is back.Complete Story » seekingalpha.com |
Salmonella Is No Danger to Vaccines This year's flu vaccine has some consumers worried. While it might protect them against a potentially deadly virus, could they end up infected with salmonella instead? online.wsj.com |
Kendall Law Group Investigates Clarient, Inc. Acquisition for Shareholders [Business Wire] - Kendall Law Group, led by former federal judge Joe Kendall, is investigating Clarient, Inc. for shareholders in connection with the proposed acquisition of the company by GE Healthcare. us.rd.yahoo.com |